Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma

Glaucoma, Open-Angle Clinical Trial

Official title:

Clinical Evaluation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) 100 mg BID Oral Administration in Patients Affected by Primary Open Angle Glaucoma (POAG): a Randomized, Double Blind Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04038034
• Other study ID #: VF-GLAU-CoQ10/2019
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2019
• Est. completion date: August 30, 2021

Study information

• Verified date: April 2020
• Source: VISUfarma SpA
• Contact: Stanislao Rizzo
• Phone: +39 06 301 54 929
• Email: stanislao.rizzo[@]policlinicogemelli.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).

Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted.

Subjects will be randomized in a 1:1 ratio to the following groups:

• group A of 35 patients treated with pressure lowering drugs and placebo;

• group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: August 30, 2021
• Est. primary completion date: August 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion criteria:

• Patient Informed consent form (ICF) signed

• M & F Aged = 40 and = 80 years at the time of the signature of ICF

• Patients with Primary Open Angle Glaucoma (POAG) stage early-moderate according to Hodapp-Parrish-Anderson criteria (MD less than -12 dB)

• Patients must be diagnosed with POAG at least 1 year before the screening visit in this study.

• Anamnesis with at least 1 value of Intraocular pressure (IOP) >21mmHg documented any time prior the initiation of the stable treatment with anti-hypertensive topical drugs.

• Patients affected by POAG and under stable treatment with anti-hypertensive topical drugs in the previous 6 months prior to enrolment to maintain IOP =18 mmHg.

• Corrected visual acuity (using ETDRS tables) = 8/10

• Transparent dioptric means to allow the examination of the OCT >25 µm.

• Pachymetry values between 500 and 600 µm.

• Patients have to show a stable visual field in the previous 6 months prior to enrolment (where by stable visual field it is intended that the patient must remain within the same stage of POAG severity (i.e. early or moderate) during the previous 6 months before the enrolment).

• Willing to follow all study procedures, including attending all site visits, tests and examinations.

• Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile.

Exclusion criteria:

• Patients with a severe defect of POAG according to Hodapp-Parrish-Anderson criteria.

• Previously diagnosed optic neuropathies.

• Diabetic retinopathy or Hypertensive retinopathy.

• Decompensated diabetes.

• Not stabilized hypertension (SAP and/or DAP) despite under adequate pharmacological treatment.

• Retinal pathologies including hereditary forms.

• Neurological, neurodegenerative or cerebrovascular conditions.

• No previous history or presence of any disease involving cornea or retina.

• Patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment (where by significant progressive opacity of lens it is intended patients who have been diagnosed with cataracts of any aetiology and for whom surgery is being considered).

• No surgical intervention for cataract in the previous 3 months prior to enrolment.

• Eye inflammatory conditions (uveitis) diagnosed any time in the patient's history.

• Treatment with topical or systemic neuroprotective agents different from CoQ10. These patients can be admitted in the study after at least a 1 month of wash-out period.

• Treatment with warfarin.

• Treatment with miotic drugs able to influence the visual field.

• Treatment with systemic or topical steroids.

• Refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical.

• Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease.

• Known drug and/or alcohol abuse.

• Mental incapacity that precludes adequate understanding or cooperation.

• Participation in another investigational study or blood donation within 3 months prior to ICF signature.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle

Intervention

Dietary Supplement:
• CoQ10- MINIACTIVES
COQUN oral formulation 100 mg BID
• Placebo
Placebo

Locations

Country	Name	City	State
Italy	UO Oculistica - PO Cisanello	Pisa	PI
Italy	U.O. di Oculistica, Fondazione Policlinico Agostino A. Gemelli,	Rome

Sponsors (1)

Lead Sponsor	Collaborator
VISUfarma SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pattern Electroretinogram Amplitude (PERG P50-N95 A)	To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (µV) observed between the two study groups.	between the baseline visit (V0) and the last study visit after 12 months of treatment (V3)
Secondary	Pattern Electroretinogram Amplitude (PERG P50-N95 A)	To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (µV) observed between the two study groups.	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary	Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT)	To evaluate the changes from baseline to each study visit between the two study groups in Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT) in milliseconds (ms)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary	Visual Evoked Potentials Implicit Times (VEP P100 IT)	To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Implicit Times (VEP P100 IT) in milliseconds (ms)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary	Visual Evoked Potentials Amplitude (VEP N75-P100 A)	To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Amplitude (VEP N75-P100 A) in microvolt (µV)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary	Visual field	To evaluate the changes from baseline to each study visit between the two study groups in Visual field (separately MD and PSD) evaluated by Humphrey field analyzer (HFA) Sita Standard 30-2	from baseline to each study visit (V1, V2, V3)
Secondary	Contrast sensitivity	To evaluate the changes from baseline to each study visit between the two study groups in Contrast sensitivity measured with Vistech tables (Vision Chart from CSO)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Secondary	Optical Coherence Tomography	To evaluate the changes from baseline to each study visit between the two study groups in Peripapillary retinal nerve fiber layer (RNFL) thickness, macular RNFL, macular ganglion cell layer (GCL), macular inner plexiform layer (IPL) assessed with natural pupils by the means of spectral domain Optical Coherence Tomography (OCT, Heidelberg Spectralis)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)